TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18412989
Drug: Antiresorptive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiresorptive therapy (e.g., hormone-replacement therapy, raloxifene, bisphosphonates)
Study: 20064989
Drug: Sodium dichloroisocyanurate
Normalized name: Sodium dichloroisocyanurate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium dichloroisocyanurate (NaDCC) tablets
Study: 16263979
Drug: Sublingual sugar
Normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual sugar administration (SG) - 2.5 g of sugar under the tongue, with subgroups of 0.1 g/kg, 0.15 g/kg, and 0.2 g/kg
Study: 16263979
Drug: Intravenous dextrose
Normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dextrose administration (IG) - 8 mL of 30% dextrose in a single bolus
Study: 16263979
Drug: Oral sugar
Normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sugar administration (OG) - 2.5 g of sugar
Study: 16263979
Drug: Water administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water administration (C)
Study: 9536540
Drug: 2% fusidic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% fusidic acid lotion (Fucidin lotion)
Study: 7906472
Drug: Topical 0.5%
Normalized name: phenol topical 0.5% topical spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.5% timolol
Study: 3300313
Drug: Norfloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin (400 mg orally twice daily)
Study: 11837758
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose glucocorticoid pulse therapy (GPT)
Study: 11837758
Drug: No glucocorticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: No glucocorticoid pulse therapy (Control)
Study: 31481504
Drug: Rituximab (R)
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab (R) at 375 mg/m2 weekly for 4 weeks and Ipilimumab (I) at 3 mg/kg on day 1 and every 3 weeks for four doses
Study: 27329896
Drug: Double taper
Normalized name: caper berry extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double taper fiber post group
Study: 25455692
Drug: Rotigotine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotigotine (up to 16 mg/24 h)
Study: 25455692
Drug: Ropinirole (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropinirole (up to 15 mg/day)
Study: 17391350
Drug: Mood episode
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mood episode or symptoms, borderline/antisocial personality disorder, male gender, living alone, hypnotic drug, drugs for physical illness
Study: 15483105
Drug: Metformin (850
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (850 mg/d) added to Flutamide (62.5 mg/d) and ethinylestradiol-drospirenone for 3 months in study A.
Study: 15483105
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of Metformin after 17 months of therapy in study B.
Study: 15483105
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group in study A (no Metformin).
Study: 15483105
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group in study B (discontinuation of Metformin).
Study: 7666090
Drug: Interferon gamma
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon gamma (IFN‐gamma) 0.2 mg total dose by subcutaneous injection daily for 6 months
Study: 2669980
Drug: GHB (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHB (50 mg GHB/kg/night given 25 mg/kg h.s. and 25 mg/kg 3 hr later)
Study: 17651517
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg Zn/d
Study: 17651517
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg Zn/d
Study: 10029243
Drug: p24-VLP (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: p24-VLP (500 microg) in alum monthly plus zidovudine 200 mg tds
Study: 8681661
Drug: High-dose continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose continuous nebulization (7.5 mg)
Study: 8681661
Drug: Standard-dose continuous
Normalized name: Uniphyllin Continus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose continuous nebulization (2.5 mg)
Study: 8681661
Drug: Standard-dose intermittent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose intermittent nebulization (2.5 mg)
Study: 8681661
Drug: High-dose intermittent
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intermittent nebulization (7.5 mg)
Study: 6753887
Drug: Oral disopyramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral disopyramide phosphate
Study: 6408949
Drug: Oral quinidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral quinidine sulfate
Study: 28386945
Drug: Diclofenac potassium
Normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac potassium for oral solution (active treatment)
Study: 18676350
Drug: Intravenous darbepoetin
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous darbepoetin alfa
Study: 18676350
Drug: Subcutaneous darbepoetin
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous darbepoetin alfa
Study: 10302610
Drug: Treatment booklet
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment booklet stressing the importance of recognizing information needs and encouraging patients to ask questions
Study: 31724048
Drug: Best Available
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Best Available Therapy
Study: 26158622
Drug: 10 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 μg hepatitis B vaccine at 0, 1 and 3 months (group A)
Study: 26158622
Drug: 10 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 μg hepatitis B vaccine at 0, 1 and 6 months (group B)
Study: 26158622
Drug: 10 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 μg hepatitis B vaccine at 0, 1 and 12 months (group C)
Study: 22944555
Drug: Ketamine-low-dose midazolam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine-low-dose midazolam (KM)
Study: 21496064
Drug: Paroxetine 20
Normalized name: PARoxetine 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine 20 mg once daily with tamsulosin 0.4 mg
Study: 21496064
Drug: Ketoconazole 400
Normalized name: ketoconazole 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole 400 mg once daily with tamsulosin 0.4 mg
Study: 15520363
Drug: Paroxetine (10-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (10-50 mg/d)
Study: 11261519
Drug: Anticardiolipin antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticardiolipin antibodies (ACA) testing
Study: 9204354
Drug: Iopentol (Imagopaque
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iopentol (Imagopaque 300 mg I/ml)
Study: 9204356
Drug: Ioxaglate (Hexabrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ioxaglate (Hexabrix 320 mg I/ml)
Study: 7524945
Drug: High-dose aprotinin
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose aprotinin (Trasylol; Bayer AG, Leverkusen, Germany) administered intraperitoneally
Study: 7524945
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no aprotinin treatment)
Study: 30703190
Drug: ADT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADT plus docetaxel (70 mg/m2 every 3 weeks for 6 cycles)
Study: 28892526
Drug: Rivaroxaban 10
Normalized name: rivaroxaban 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 10 mg/d for 5 days followed by 15 or 20 mg/d
Study: 28892526
Drug: Warfarin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin with a target INR of 2.0-3.0 for 4 weeks
Study: 23299607
Drug: Oral cholecalciferol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cholecalciferol, 2000 IU/d
Study: 20853132
Drug: Metronomic etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Metronomic etoposide (50 mg/m2 daily for 21 consecutive days each month) with bevacizumab (10 mg/kg every 2 weeks)
Study: 20853132
Drug: Metronomic temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Metronomic temozolomide (50 mg/m2 daily) with bevacizumab (10 mg/kg every 2 weeks)
Study: 20001979
Drug: Carvedilol (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (in combination with nifedipine)
Study: 20001979
Drug: Carvedilol (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (in combination with nifedipine, metformin, and simvastatin)
Study: 17408310
Drug: Other QTc
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other QTc interval-prolonging drugs
Study: 3069521
Drug: Nimesulide 200
Normalized name: nimesulide 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimesulide 200 mg/day for 7 days
Study: 3069521
Drug: Flurbiprofen 300
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flurbiprofen 300 mg/day for 7 days
Study: 28950757
Drug: Infusion bag
Normalized name: LIFILEUCEL INJ,SUSP INFUSION BAG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion bag (IB) technique
Study: 21193871
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human TSH (0.9 mg injections on days 1 and 2)
Study: 17114205
Drug: Intravenous disodium
Normalized name: BALSALAZIDE DISODIUM
DrugBank: Balsalazide (DB01014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous disodium pamidronate (APD) given as monthly infusions
Study: 17114205
Drug: Intravenous disodium
Normalized name: BALSALAZIDE DISODIUM
DrugBank: Balsalazide (DB01014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous disodium pamidronate (APD)
Study: 14574343
Drug: Snack (58.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Snack (58.5 g chocolate-based)
Study: 1718700
Drug: Nifedipine 30
Normalized name: nifedipine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 30 to 120 mg/day, initiated as early as 3 hours after onset of symptoms, for up to 6 months
Study: 1718700
Drug: Nifedipine 30
Normalized name: nifedipine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 30 mg/day, started 7 to 21 days after infarction
Study: 7049112
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy using cyclophosphamide, methotrexate, and vincristine for 30 weeks
Study: 24550581
Drug: Levosimendan pretreatment
Normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan pretreatment (Group L)
Study: 22232535
Drug: Transrectal ultrasound
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transrectal ultrasound guided biopsy under antibiotic cover
Study: 15891249
Drug: Adapalene gel
Normalized name: Adapalene Gel
DrugBank: Adapalene (DB00210)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adapalene gel 0.1% with doxycycline
Study: 9469998
Drug: Surfactant (beractant)
Normalized name: Beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Surfactant (beractant) 100 mg/kg, four doses before ECMO and four additional doses during ECMO if required
Study: 7610735
Drug: Diltiazem (0.25-0.30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (0.25-0.30 mg/kg BW)
Study: 7610735
Drug: Disopyramide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disopyramide (50 mg)
Study: 28108992
Drug: Intralesional injection
Normalized name: DEXAMETHASONE SODIUM PHOSPHATE 4 mg in 1 mL INTRALESIONAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional injection of candida antigen, repeated every 3 weeks until complete improvement or for a maximum of three sessions.
Study: 28108992
Drug: Intralesional injection
Normalized name: DEXAMETHASONE SODIUM PHOSPHATE 4 mg in 1 mL INTRALESIONAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional injection of candida antigen
Study: 28108992
Drug: Intralesional immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional immunotherapy
Study: 15285777
Drug: Levodopa treatment
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levodopa treatment
Study: 8768057
Drug: 0.06 mg
Normalized name: urea 0.06 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.06 mg ethinyl estradiol (EE2) for 14 days followed by 0.04 mg EE2 and 0.125 mg levonorgestrel for 12 days
Study: 8768057
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment over 26 days
Study: 7073148
Drug: Low-dose heparin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose heparin prophylaxis
Study: 2148697
Drug: Adjusted-dose heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjusted-dose heparin treatment and various schedules of warfarin prophylaxis
Study: 2148697
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin fractions or fragments
Study: 7028242
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy with intravenous Poly I:C
Study: 7028242
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy without intravenous Poly I:C
Study: 28671095
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of locking plate and anti-osteoporosis drug
Study: 28671095
Drug: Simple locking
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple locking plate treatment
Study: 25048788
Drug: Kaledo board
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kaledo board game intervention introduced weekly for 20 weeks
Study: 21227890
Drug: VCS 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: VCS 0.4 mg kg(‐1) BID
Study: 21227890
Drug: VCS 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: VCS 0.3 mg kg(‐1) BID
Study: 21227890
Drug: VCS 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: VCS 0.2 mg kg(‐1) BID
Study: 17566806
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg ebastine daily (monotherapy)
Study: 31486684
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (not specified)
Study: 15020174
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch therapy alone or in combination with the Committed Quitters(R) program, and individual counseling (if applicable)
Study: 15020174
Drug: Psychosocial treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychosocial treatment in addition to patch therapy
Study: 15020174
Drug: Free smoking
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free smoking cessation treatment offered in primary care settings
Study: 27165949
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of aspirin
Study: 16224050
Drug: Atorvastatin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (80 mg/daily)
Study: 10091727
Drug: 5-fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil (5-FU) at 375 mg/m2 and levofolinic acid (1-FA) at 100 mg/m2 for 5 consecutive days with recombinant interferon-2b (IFN) at 3 MU/day for 7 days starting 2 days before chemotherapy administration.
Study: 10091727
Drug: 5-fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil (5-FU) at 375 mg/m2 and levofolinic acid (1-FA) at 100 mg/m2 for 5 consecutive days without recombinant interferon-2b (IFN).
Study: 10091727
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with limited liver involvement (regardless of chemotherapy arm).
Study: 10091727
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with massive liver involvement (regardless of chemotherapy arm).
Study: 1685667
Drug: Beta-adrenoceptor blockers
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-adrenoceptor blockers (Atenolol and Epanolol)
Study: 22437068
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no drug treatment)
Study: 7112697
Drug: disodium cromoglycate
Normalized name: Disodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: disodium cromoglycate eye drops 2% and chlorpheniramine tablets 2 mg as supplementary treatment
Study: 24345444
Drug: Memantine (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine (titrated to 10 mg twice daily)
Study: 21924636
Drug: Tranexamic acid,
Normalized name: Tranexamic Acid, 650 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tranexamic acid, 10 mg/kg bolus before surgery followed by 1 mg/kg/h infusion during surgery
Study: 19620954
Drug: Zolpidem (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem (10 mg per feeding tube)
Study: 15111672
Drug: 5-HT1A receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-HT1A receptor binding potential measured with PET and [Carbonyl-11C]WAY-100 635
Study: 11177010
Drug: Propofol, 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol, 0.5 mg/kg
Study: 11177010
Drug: Metoclopramide hydrochloride,
Normalized name: Metoclopramide Hydrochloride, 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide hydrochloride, 0.2 mg/kg
Study: 9674679
Drug: Braun Oral
Normalized name: bran Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Braun Oral B Plaque Remover (D7) with dedicated orthodontic brush head OD5‐1 (Braun AG, Germany)
Study: 9674679
Drug: Manual dedicated
Normalized name: liver,desiccated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual dedicated orthodontic toothbrush (P35, Oral B Laboratories, Calif.)
Study: 7913731
Drug: MN rgp120
Normalized name: Mn 2+
Approvals — FDA: no, EMA: no, PMDA: no
Description: MN rgp120 vaccine (100 micrograms, 300 micrograms, or 600 micrograms)
Study: 7913731
Drug: MN rgp120
Normalized name: Mn 2+
Approvals — FDA: no, EMA: no, PMDA: no
Description: MN rgp120 vaccine (three doses)
Study: 3422262
Drug: IT MTX
Approvals — FDA: no, EMA: no, PMDA: no
Description: IT MTX plus intravenous (IV) high-dose MTX (HDMTX)
Study: 31190322
Drug: Phenylephrine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine (50 µg)
Study: 31190322
Drug: Ephedrine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine (5 mg)
Study: 25244665
Drug: Isonicotinic acid
Normalized name: Isonicotinic acid
DrugBank: Isonicotinic acid (DB16884)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isonicotinic acid hydrazide (INH) 900 mg
Study: 25244665
Drug: Misoprostol 25
Normalized name: Misoprostol 25 microgram vaginal tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol 25 μg
Study: 23040783
Drug: Domestic imipenem
Normalized name: Imipenem
DrugBank: Imipenem (DB01598)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Domestic imipenem cilastatin sodium 1.0 g intravenous drip, every 6-8 hours for 7-14 days
Study: 23040783
Drug: Imported injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imported injection imipenem cilastatin sodium 1.0 g intravenous drip, every 6-8 hours for 7-14 days
Study: 7541190
Drug: Clobetasol propionate
Normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Clobetasol propionate (0.05%) ointment
Study: 943169
Drug: Base ointment
Normalized name: Unibase Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Base ointment
Study: 2132086
Drug: K-Mg aspartate
Normalized name: aspartate
DrugBank: Potassium aspartate (DB15819)
Approvals — FDA: no, EMA: no, PMDA: no
Description: K-Mg aspartate
Study: 2132086
Drug: Mg aspartate
Normalized name: Magnesium Aspartate 65 MG Oral Tablet [MG ASPARTATE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mg aspartate
Study: 499960
Drug: Card-Dusodril 1/8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Card-Dusodril 1/8 (0.5 mg digoxin)
Study: 499960
Drug: Card-Dusodril 1/4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Card-Dusodril 1/4 (1 mg digoxin)
Study: 26696112
Drug: Intranasal midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal midazolam (0.2mg/kg)
Study: 26696112
Drug: Sublingual midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sublingual midazolam (0.2mg/kg)
Study: 22469098
Drug: AZD2066 13
Normalized name: AZD2066
DrugBank: AZD2066 (DB17078)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD2066 13 mg
Study: 22469098
Drug: AZD2066 2
Normalized name: AZD2066
DrugBank: AZD2066 (DB17078)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD2066 2 mg
Study: 22469098
Drug: AZD2066 6
Normalized name: AZD2066
DrugBank: AZD2066 (DB17078)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD2066 6 mg
Study: 18468271
Drug: Orofacial myofunctional
Normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orofacial myofunctional therapy (OMT)
Study: 11808830
Drug: Neoral (175
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoral (175 mg)
Study: 11808830
Drug: Sandimmune (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sandimmune (300 mg)
Study: 25293524
Drug: 1.25 mg
Normalized name: menthol 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg droperidol
Study: 7750190
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human GH (rhGH) at an initial dosage of 2 IU/m2 body surface/day, increased if height velocity increment was less than 2 cm/year